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Drug–drug conditioning between citalopram and haloperidol or 
olanzapine in a conditioned avoidance response model: 
implications for polypharmacy in schizophrenia
Nathan L. Sparkman and Ming Li
Department of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA
Abstract
Patients with schizophrenia often have anxiety and depression, and thus are treated with multiple 
psychotherapeutic medications. This practice of polypharmacy increases the possibility for drug–
drug interactions. However, the pharmacological and behavioral mechanisms underlying drug–
drug interactions in schizophrenia remain poorly understood. In the present study, we adopted a 
preclinical approach and examined a less known behavioral mechanism, drug–drug conditioning 
(DDC) between haloperidol (a typical antipsychotic) or olanzapine (atypical antipsychotic) and 
citalopram (a selective serotonin reuptake inhibitor). A rat two-way conditioned avoidance 
response paradigm was used to measure antipsychotic activity and determine how DDC may alter 
the antipsychotic efficacy in this model. Following acquisition of the avoidance response, rats 
were then randomly assigned to receive vehicle, citalopram (10.0 mg/kg, intraperitoneally), 
haloperidol (0.05 mg/kg, subcutaneously), olanzapine (1.0 mg/kg, subcutaneously), combined 
haloperidol with citalopram, or combined olanzapine with citalopram treatment for seven 
avoidance test sessions. In comparison with antipsychotic treatment alone, combined treatment 
with citalopram potentiated the antiavoidance effect of olanzapine or haloperidol (to a lesser 
extent) during the seven drug-test sessions. In addition, repeated pairing of citalopram with 
haloperidol or olanzapine caused citalopram to show a newly acquired avoidance-disruptive 
effect. This effect was context specific because citalopram paired with haloperidol or olanzapine 
outside the avoidance testing context (i.e. home cages) did not show such an effect. These findings 
indicate that concurrent antidepressant and antipsychotic treatments may engender a DDC process 
that follows the general Pavlovian associative conditioning principles. They also indicate that 
adjunctive citalopram treatment may enhance the antipsychotic efficacy of haloperidol and 
olanzapine in the treatment of schizophrenia.
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Introduction
Depression is a common comorbidity in schizophrenia, affecting an estimated 50% of 
patients (Buckley, 2008), and this symptom is often unabated by traditional antipsychotic 
regimens. Polypharmacy regimens have often sought to alleviate the depression-related 
symptoms by coprescribing an antidepressant along with an antipsychotic drug (Zink et al., 
2010). For example, citalopram (CIT), a selective serotonin reuptake inhibitors (SSRIs) used 
for the treatment of major depression (ZumBrunnen and Jann, 1998; Sepehry et al., 2007), is 
often used as an adjunctive therapy with traditional antipsychotics in the treatment of 
comorbid anxiety and depression symptoms in schizophrenia (Salokangas et al., 1996; 
Friedman et al., 2005). This practice of polypharmacy has raised some concerns on the 
efficacy, costs, and possible adverse effects of drug–drug interactions (Alfaro, 2001; 
Sandson et al., 2005; Conley and Kelly, 2007; Rupnow et al., 2007). Some reports suggest 
that antidepressants such as citalopram are effective in the treatment of depression in 
schizophrenia with concurrent antipsychotic drug treatment (Englisch et al., 2009; Zisook et 
al., 2009). However, other reports question the efficacy of add-on SSRI in the improvement 
of negative symptoms (Sepehry et al., 2007). Overall, evidence on augmentation of 
antipsychotics with SSRIs remains inconclusive. Also, it is not clear whether the efficacy of 
antidepressants or antipsychotics is altered in the combined drug treatment regimens. Zink et 
al. (2010) report that there is an urgent need to conduct well-designed randomized-
controlled trials on the use of antidepressants in schizophrenia. Without controlled trials and 
mechanistic investigations, it is difficult to assess the extent and nature of drug–drug 
interactions of antidepressants and antipsychotics in the treatment of schizophrenia 
(ZumBrunnen and Jann, 1998).
In almost all polypharmacy studies, the focus has been on two major varieties of drug–drug 
interactions: pharmacodynamic interactions and pharmacokinetic interactions (Sandson et 
al., 2005). Concurrent drug use can also result in a drug–drug conditioning (DDC) 
phenomenon that is less understood by psychiatrists. Similar to Pavlovian conditioning 
involving exteroceptive stimuli (e.g. light, sound, food, or shock), DDC is found to be 
mediated by the same learning principles (Revusky et al., 1979; Taukulis and Brake, 1989). 
Taukulis and Brake (1989) reported that the anxiolytic effect of diazepam can be potentiated 
by repeatedly pairing it with chlorpromazine. They injected rats with diazepam (2.5 mg/kg), 
followed 30 min later by chlorpromazine (10.0 mg/kg). After 10–12 repeated drug pairings 
of this type, the anxiolytic responses of the animals to diazepam alone were tested in an 
elevated plus maze task. They found that rats previously conditioned with diazepam and 
chlorpromazine spent more time in the open arms than rats conditioned with either diazepam 
alone or chlorpromazine, followed 30 min later by diazepam (backward pairings). The 
results showed that the order of the drugs during the conditioning period was critical to 
developing the enhanced anxiolytic effect of diazepam. They later found the same effect 
with diazepam–haloperidol (HAL) pairings. Interestingly, other dopamine (DA) antagonists 
(thioridazine and pimozide) did not produce an enhanced conditioned response (Taukulis et 
al., 1992). This enhanced anxiolytic effect is believed to be caused by the interdrug 
conditioning, an internal associative process, rather than pharmacological alteration because 
reversing the order of the drug treatment does not change the anxiolysis of diazepam.
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Following a similar approach, we recently examined possible DDC between haloperidol (a 
typical antipsychotic) and chlordiazepoxide (a benzodiazepine anxiolytic) and the DDC 
between olanzapine (atypical antipsychotic) and chlordiazepoxide in a conditioned 
avoidance response (CAR) model (Li et al., 2009). The CAR has been used for the detection 
of antipsychotic activity for more than 60 years and shows high predictive validity, as most 
antipsychotics at clinically relevant doses disrupt avoidance responding preferentially (Arnt, 
1982; Franberg et al., 2008; Porsolt et al., 2010; Wadenberg, 2010). Our results show that 
the repeated concurrent chlordiazepoxide and olanzapine treatment attenuated the 
antiavoidance effect of olanzapine. However, chlordiazepoxide acquired a haloperidol-like 
property in disrupting avoidance responding after being paired repeatedly with haloperidol.
The present study used a similar DDC approach and examined how the antidepressant 
citalopram interacts with haloperidol or olanzapine (OLZ) in the CAR model. It is known 
that both haloperidol and olanzapine disrupt avoidance responding whereas citalopram has 
not been shown to disrupt avoidances effectively (Sun et al., 2010). Therefore, it may be 
possible that following repeated pairings, citalopram may acquire the avoidance-disruptive 
effect of haloperidol or olanzapine. However, repeated combined treatment of citalopram 
with haloperidol or olanzapine may alter the effectiveness of haloperidol or olanzapine to 
disrupt avoidance. In the present study, citalopram served as a neutral cue [conditioning 
stimulus (CS)] that signals that the effects of haloperidol or olanzapine [unconditioned 
stimulus (US)] were imminent. Over time, through repeated pairings, citalopram acquired 
the avoidance-disruptive property of haloperidol and olanzapine, and also potentiated the 
avoidance-disruptive effect of these drugs. These findings indicate that adjunct citalopram 
treatment may enhance the antipsychotic efficacy of haloperidol and olanzapine.
Methods
Subjects
Male Sprague–Dawley rats (226–250 g upon arrival; Charles River Laboratories, Potage, 
Michigan, USA) were housed two per cage in 48.3 cm × 26.7 cm × 20.3 cm transparent 
polycarbonate cages under 12-h light/dark conditions (light on between 06:30 and 18:30 h). 
Room temperature was maintained at 21±1° with a relative humidity of 45–60%. Food and 
water were freely available. Animals were allowed at least 1 week of habituation to the 
animal facility before being used in the experiments. All procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Nebraska, Lincoln.
Avoidance conditioning apparatus
Eight identical two-way shuttle boxes, custom designed and manufactured by Med 
Associates (St Albans, Vermont, USA), were used. Each box was housed in a ventilated, 
sound-insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 
64 cm long, 30 cm high (from grid floor), and 24 cm wide, and divided into two equal-sized 
compartments by a white PVC partition with an arch-style doorway (15 cm H × 9 cm W at 
base). An aluminum hurdle (4 cm high) was placed between the two compartments; thus, the 
rats had to jump from one compartment to enter the other. The grid floor consisted of 40 
stainless-steel rods, spaced 1.6 cm apart center to center, through which a scrambled 
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footshock (0.8 mA) was delivered by a constant current shock generator (Model ENV-410B) 
and scrambler (Model ENV-412). The rat’s location and motor activity were detected by a 
set of 16 photobeams (ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid 
floor). A speaker (ENV-224AMX) mounted on the ceiling of the cubicle, centered above the 
shuttle box, was used to provide a CS (76 dB white noise). All the training and testing 
procedures were controlled by Med Associates programs running on a computer. 
Background noise (~ 74 dB) was provided by a ventilation fan affixed at the top corner of 
each isolation cubicle.
Experiment 1: Effects of repeated citalopram and haloperidol pairing on avoidance 
responding to citalopram and haloperidol
The experiment comprised of three phases: avoidance training, DDC, and drug testing (see 
Fig. 1 for the procedural details).
Avoidance training phase—Forty rats were first handled and habituated to the 
avoidance conditioning apparatus for two days (30 min/day), and then trained for 10 
consecutive days to acquire robust conditioned avoidance responding (> 70% avoidance 
trials). Each training session consisted of 30 discrete trials. Every trial started by presenting 
white noise (CS, 76 dB) for 10 s, followed by a continuous footshock (US, 0.8 mA, 
maximum 5 s) on the grid floor. If a subject moved from one compartment into the other 
within the 10 s of CS presentation, the shock was prevented, and this shuttling response was 
recorded as avoidance (a two-way avoidance). If the rat remained in the same compartment 
for more than 10 s and made a crossing upon receiving the footshock, this response was 
recorded as escape. If the rat did not respond during the entire 5-s presentation of the shock, 
the trial was terminated and escape failure was recorded. Intertrial intervals varied randomly 
between 30 and 60 s.
Drug conditioning phase—At the end of the training phase, 32 rats that had fulfilled the 
training criterion (≥ 70% avoidance in each of the last two sessions) were used in the drug 
conditioning phase. They were matched and then assigned randomly to one of the four 
groups. The drug conditioning phase consisted of a 3-day cycle and was repeated seven 
times over a 21-day period. On day 1, each group was administered a double injection of 
one of the following combinations: CIT + VEH (n = 8), VEH + HAL (n = 8), CIT + HAL (n 
= 8), and VEH + VEH (n = 8). The first injection (CIT 10.0 mg/kg, or sterile water, 1.0 
ml/kg, intraperitoneally) was administered 15 min before the second injection (HAL 0.05 
mg/kg, or sterile water, 1.0 ml/kg, subcutaneously). One hour after the second injection, rats 
were placed in the avoidance conditioning boxes and tested. On day 2, rats in the CIT + 
VEH, VEH + HAL, and CIT + HAL groups received a single injection of HAL, CIT, and 
VEH, respectively, whereas the VEH + VEH group received a double injection of CIT and 
HAL separated by 15 min. Immediately after the injections, rats were returned to their home 
cages. No avoidance test was carried out on this day. The purpose of giving rats the drug 
treatments on day 2 and not testing them was to ensure that every rat received the same drug 
treatment (all rats had CIT, HAL, and VEH), although in different contexts (e.g. home cage 
vs. CAR boxes) and with different drug injection intervals (15 min vs. 24 h), so that the 
specific DDC effect on avoidance behavior could be assessed. On day 3, all rats were 
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untreated and unhandled. Following the seven cycles of the conditioning procedure, all rats 
were retrained drug-free in two consecutive sessions to bring back a high level of avoidance 
responding.
Drug testing phase—The drug testing phase started 24 h after the last retraining session. 
Rats were first injected with CIT (10.0 mg/kg, intraperitoneally) and tested 75 min later. The 
next day, rats were retrained drug-free, and 1 day later, tested again under HAL (0.025 
mg/kg, subcutaneously, − 60 min) to assess the HAL sensitization effect (Li et al., 2010; 
Mead and Li, 2010; Zhang and Li, 2012). For both drug tests, the same conditioned 
avoidance procedure was used, except that only the CS was presented in the 30 trials. No 
shock US was ever presented.
Experiment 2: Effects of repeated citalopram and olanzapine pairing on avoidance 
responding to citalopram and olanzapine
This experiment was identical to experiment 1, except that HAL was replaced by OLZ. 
Forty rats were used, of which 32 rats that fulfilled the learning criterion were used in the 
drug testing. They were assigned to one of the following four groups: CIT + VEH (n = 8), 
VEH + OLZ (n = 8), CIT + OLZ (n = 8), and VEH + VEH (n = 8), and were subjected to the 
seven sessions of drug conditioning and two sessions of drug testing (the CIT test, followed 
by the OLZ 0.5 mg/kg test) to assess the CIT conditioning effect and the OLZ sensitization 
effect.
Drugs
The injection solutions of HAL (5 mg/ml ampoules, Shanghai Xudong Haipu 
Pharmaceutical Co., Shanghai, China) and CIT (Toronto Research Chemicals Inc., Toronto, 
Ontario, Canada) were obtained by mixing drugs with sterile water. OLZ (a gift from the 
National Institute of Mental Health drug supply program) was dissolved in 1.5% glacial 
acetic acid in distilled water. HAL and OLZ were administered subcutaneously, whereas 
CIT was administered intraperitoneally. The doses of HAL (0.05 mg/kg) and OLZ (1.0 
mg/kg) and their injection route were chosen on the basis of (a) previous work showing that 
at the chosen doses, HAL and OLZ injected subcutaneously produce a comparable 
progressive across-session decrease in avoidance responding (Li et al., 2007) and (b) rat 
brain D2 receptor occupancy data showing that both drugs induce clinically comparable 
levels of D2 occupancy (65–80%) (Kapur et al., 2003). The choice of the CIT dose (10 
mg/kg) and its route of injection was made on the basis of the findings showing that (a) CIT 
(10 mg/kg) is ineffective in disrupting avoidance responding (Sun et al., 2010) and (b) CIT 
at this dose is effective in several aversively conditioned paradigms, such as Pavlovian fear 
conditioning (Hashimoto et al., 2009; Sun et al., 2010).
This time interval between CIT and HAL or OLZ (15 min) was determined so that there was 
sufficient time for the drug effects of HAL or OLZ and CIT to overlap. The half-lives of 
CIT, HAL, and OLZ in rats are 3 h (Hyttel et al., 1984), 1.5 h (Cheng and Paalzow, 1992), 
and 2.5 h (Aravagiri et al., 1999), respectively. This arrangement ensures that the two drugs 
had sufficient concurrency of the effective drug states that would be suitable for DDC. A 
similar kind of DDC arrangement had been used by Taukulis and Brake (1989). To 
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determine possible behavioral sensitization induced by repeated HAL or OLZ treatment, 
HAL and OLZ were administered at half of their training doses during the last test session 
(0.025 and 0.5 mg/kg, respectively) (Li et al., 2010; Zhang and Li, 2012).
Statistics
The main dependent variable was the number of avoidance responses. All data are expressed 
as mean ± SEM. Data from the DDC phase were first analyzed using a mixed-model 
repeated-measures analysis of variance (ANOVA) with CIT (CIT vs. VEH, two levels), 
HAL (HAL vs. VEH, two levels), or OLZ (OLZ vs. VEH, two levels) as the between-
subjects factor and the test sessions (i.e. seven drug sessions) as the within-subjects factor, 
followed by post-hoc Fisher’s protected least squared difference to identify the significant 
group differences. A similar repeated-measures analysis was used for the two consecutive 
drug-free retraining days. For the drug challenge test days (CIT, HAL, or OLZ challenge 
tests), because we had an a-priori hypothesis on the basis of our previous work (Li et al., 
2009), a series of planned comparisons instead of post-hoc tests were used to identify 
significant differences between groups. A conventional two-tailed level of significance at 
the 5% level was used.
Results
Experiment 1: Effects of repeated citalopram and haloperidol pairing on avoidance 
responding to citalopram and haloperidol
CIT and HAL: conditioning—HAL potently and progressively attenuated avoidance 
responding (Fig. 2a). There was a significant main effect of HAL [F(1,28) = 316.56, P < 
0.001] as well as a significant HAL × Session interaction [F(6,168) = 14.47, P < 0.001]. The 
main effect of CIT was marginally significant [F(1,28) = 4.17, P = 0.05], whereas the CIT × 
Session interaction was not significant. Examination of the pattern of avoidance responding 
across sessions showed that rats treated with VEH + VEH maintained a high level of 
responding, whereas rats treated with CIT + VEH had somewhat attenuated responding. The 
VEH + HAL rats showed a rapid and progressive attenuation across test sessions and those 
treated with CIT + HAL tended to have the lowest levels of avoidance responding.
CIT did not alter the number of escape failures. However, there was a significant main effect 
of HAL [F(1,28) = 26.01, P < 0.001] and a significant HAL × Session interaction [F(6,168) 
= 14.06, P < 0.001], wherein animals treated with HAL showed a progressive increase in 
their number of escape failures across test sessions (Fig. 2b).
CIT and HAL: drug-free retraining—During the subsequent two drug-free retraining 
sessions, rats that had received HAL treatment (i.e. VEH + HAL or CIT + HAL) recovered 
avoidance responding (Fig. 2a). There was a significant CIT × HAL × Session interaction 
[F(1,28) = 70.05, P < 0.02], a significant CIT × Session interaction [F(1,28) = 7.05, P < 
0.02], and a significant HAL × Session interaction [F(1,28) = 31.54, P < 0.001], wherein 
rats treated with VEH + HAL performed the least number of avoidance responses on the 
first retraining day, whereas those that received CIT + HAL performed at intermediate levels 
and those that received VEH + VEH or CIT + VEH performed the highest number of 
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avoidance responses. On the first day of retraining, there were significant main effects of 
HAL [F(1,28) = 34.50, P < 0.001] and CIT (F(1,28) = 6.30, P < 0.02) and a significant CIT 
× HAL interaction [F(1,28) = 6.88, P < 0.02]. One-way ANOVA, followed by post-hoc 
analysis showed that rats that had been treated previously with CIT + HAL made 
significantly fewer avoidance responses than those treated previously with VEH + VEH or 
CIT + VEH (P < 0.05). Furthermore, rats treated previously with VEH + HAL performed 
fewer avoidance responses than the VEH + VEH, CIT + VEH, or CIT + HAL rats. On the 
second retraining day, there was a significant main effect of HAL [F(1,28) = 9.75, P < 
0.005], wherein rats treated with HAL made significantly fewer avoidance responses than 
those not treated previously with HAL.
On escape failures, across the two-day retraining period (Fig. 2b), there were significant 
effects of CIT [F(1,28) = 5.10, P < 0.05], HAL [F(1,28) = 9.52, P < 0.005], and the CIT × 
HAL interaction [F(1,28) = 10.05, P < 0.005]. In addition, there was a significant HAL × 
Session interaction [F(1,28) = 9.75, P < 0.005]. Post-hoc analysis showed that during the 
first retraining session, rats that had been treated in the shuttle box with VEH + HAL had a 
greater number of escape failures than those treated with CIT + HAL, CIT + VEH, or VEH 
+ VEH.
CIT and HAL: CIT challenge test—During the CIT test, all rats were treated with CIT 
(10.0 mg/kg, intraperitoneally) to determine the DDC effects of CIT to HAL (Fig. 3). 
Planned comparisons of the four conditioning groups showed that rats treated with VEH + 
VEH or CIT + VEH did not differ from each other and maintained a high level of avoidance 
responding. Rats that had been treated previously with VEH + HAL also did not differ 
significantly from these two groups. However, rats had been conditioned to CIT + HAL 
showed the fewest avoidance responses and were significantly different from the VEH + 
VEH or the CIT + VEH rats (P values < 0.05). This indicates that CIT + HAL conditioning 
resulted in CIT acquiring the avoidance-disrupting effects of HAL. In addition, this effect 
was specific to the conditioned effects of the drugs in the testing context because rats that 
received CIT + HAL pairings in their home cage did not show this effect.
CIT and HAL: HAL challenge test—Following a subsequent retraining day (no group 
differences present; Fig. 4, inset), all rats were administered a 0.025 mg/kg HAL injection 
and their avoidances were tested 1 h later to assess HAL sensitization (Fig. 4) (Li et al., 
2010). Planned comparisons showed no difference between rats treated previously with CIT 
+ VEH or VEH + VEH. However, rats treated previously with VEH + HAL or CIT + HAL 
performed significantly fewer avoidance responses than the CIT + VEH or VEH + VEH 
groups (P values < 0.05). There were also no differences between the two HAL groups. 
These data indicate that repeated administration of HAL induced a long-lasting sensitization 
effect in avoidance disruption, consistent with our previous finding (Li et al., 2007; Zhang 
and Li, 2012). In addition, CIT did not alter the efficacy of HAL even after repeated 
pairings.
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Experiment 2: Effects of repeated citalopram and olanzapine pairing on avoidance 
responding to citalopram and olanzapine
CIT and OLZ: conditioning—Repeated administration of OLZ potently and 
progressively attenuated avoidance responding across the seven drug test sessions (Fig. 5a). 
In contrast, rats treated with VEH + VEH or CIT + VEH maintained a high level of 
responding, and they did not differ from one another. There was a significant main effect of 
OLZ [F(1,28) = 316.56, P < 0.001] and a significant OLZ × Session interaction [F(6,168) = 
13.76, P < 0.001]. In addition, there was a significant main effect of CIT [F(1,28) = 316.56, 
P < 0.001] and a significant CIT × Session interaction [F(6,168) = 30.05, P < 0.01], wherein 
CIT reduced the number of avoidance responses. This was especially evident during the first 
four drug-test sessions.
Analysis of escape failures showed that repeated administration of OLZ progressively 
increased the number of escape failures across sessions (Fig. 5b). Rats treated with VEH + 
VEH or CIT + VEH maintained very low levels of escape failures and they did not differ 
from one another. There was a significant main effect of OLZ [F(1,28) = 34.37, P < 0.001] 
and a significant OLZ × Session interaction [F(6,168) = 13.87, P < 0.001].
CIT and OLZ: drug-free retraining—During the subsequent two drug-free retraining 
sessions, rats that had received OLZ treatment recovered at a slower rate compared with 
VEH-treated rats or rats that received CIT alone. A repeated-measures ANOVA showed a 
significant main effect of OLZ [F(1,28) = 16.66, P < 0.001; Fig. 5a]. Rats that had been 
treated previously with VEH + OLZ or CIT + OLZ made significantly fewer avoidance 
responses on both days. The VEH + OLZ and CIT + OLZ groups were significantly 
different from the VEH + VEH or CIT + VEH groups (P’s < 0.05) on the first retraining 
day. The CIT + OLZ group was still significantly different from the VEH + VEH or the CIT 
+ VEH group on the second retraining day (P < 0.05).
In terms of escape failures, there was a significant main effect of OLZ [F(1,28) = 4.412, P < 
0.05; Fig. 5b]; however, the difference between group means was less than one trial and was 
probably not psychologically significant.
CIT and OLZ: CIT challenge test—Following two retraining days, all rats were treated 
with CIT to determine the DDC effect of CIT to OLZ (Fig. 6). Rats treated with VEH + 
VEH or CIT + VEH during the DDC sessions maintained a high level of avoidance 
responding and they did not differ from one another. Also, rats treated with VEH + OLZ 
were not different from any group. However, planned comparisons showed that rats that had 
been treated previously with CIT + OLZ made significantly fewer avoidance responses than 
CIT + VEH (P < 0.005) or VEH + VEH (P < 0.005). This indicates that CIT + OLZ 
conditioning resulted in CIT acquiring the avoidance-disrupting effects of OLZ. In addition, 
this effect was specific to the conditioned effects of the drugs in the testing context because 
animals that experienced CIT + OLZ pairings in their home cage did not show this effect.
CIT and OLZ: OLZ challenge—On the subsequent retraining day, although they 
achieved an average of 25.5 avoidances, rats conditioned with CIT + OLZ still made 
significantly fewer avoidance responses than those conditioned with CIT + VEH or VEH + 
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VEH (P < 0.05; Fig. 7, inset). To examine the long-term sensitization effect of OLZ (Li et 
al., 2010; Mead and Li, 2010; Zhang and Li, 2012), all rats were administered a 0.5 mg/kg 
OLZ injection and their avoidances were tested (Fig. 7). One-way ANOVA showed a 
significant effect of group [F(3,28) = 13.73, P < 0.001] and subsequent planned 
comparisons showed that rats treated previously with VEH + OLZ or CIT + OLZ during the 
DDC phase made significantly fewer avoidance responses than those treated previously with 
VEH + VEH (P values < 0.05). Interestingly, rats previously conditioned to CIT + VEH also 
made fewer avoidance responses than the VEH + VEH-treated rats (P < 0.001), but more 
than the rats conditioned to CIT + OLZ (P < 0.04) or VEH + OLZ (P < 0.02). These results 
indicate that CIT + VEH treatment also enhanced rats’ sensitivity to the avoidance-
disruptive effect of OLZ. However, this effect was weak in comparison with the effects of 
OLZ treatment and was dependent on the context of the drug experience, as the VEH + VEH 
rats receiving CIT + OLZ pairings in their home cage did not show this enhanced sensitivity.
Discussion
In two separate studies, we examined how the SSRI CIT interacted behaviorally with the 
typical antipsychotic HAL or the atypical antipsychotic OLZ as a means to examine the 
impact of polypharmacy treatment in schizophrenia. Our results clearly show that when two 
psychotropic drugs are used together, their behavioral effects could be altered by a DDC 
mechanism. For example, CIT by itself does not have an intrinsic disruptive effect on the 
CAR (Figs 2a and 5a) (Sun et al., 2010): however, after repeated pairings with HAL or 
OLZ, it acquired an antiavoidance property (Figs 3 and 6). This ‘acquired’ avoidance-
disruptive effect of CIT was attributed specifically to DDC, wherein CIT functioned as the 
drug CS and HAL or OLZ as the drug US (Taukulis and Brake, 1989), and could not be 
attributed to the simple pharmacological effects of the drugs, as no such effect was found in 
the control groups (e.g. the CIT + VEH, VEH + HAL, or VEH + OLZ), even though they 
received the same numbers of CIT and HAL or OLZ injections separated by 24 h. We also 
found that, to induce the antiavoidance effect in the CIT group, CIT + HAL or CIT + OLZ 
pairing had to occur within the context of avoidance testing. Rats that received this pairing 
in their home cages (i.e. VEH + VEH rats) did not show altered drug efficacy in the CAR 
procedure. These findings indicate that the drug conditioning is context specific. They also 
indicate that the drug conditioning effects follow the same general associative conditioning 
principles found in a typical Pavlovian conditioning paradigm in which a deliberate CS–US 
pairing is required (Domjan, 2005).
In addition, the combined treatment of CIT with HAL or OLZ potentiated the avoidance-
disruptive effect of HAL and OLZ during the DDC phase. This effect may be mediated by 
the pharmacological mechanisms associated with the pharmacokinetic or pharmacodynamic 
interactions of the drugs. Pharmacokinetically, most antipsychotics and SSRIs are 
metabolized through the CYP isozyme system (mainly CYP1A2, CYP2D6, and CYP3A4) 
and, as a result, SSRIs can inhibit the metabolism of antipsychotic drugs (ZumBrunnen and 
Jann, 1998). In the case of CIT (CYP2C19, CYP2D6, and CYP3A4) (Spina et al., 2008), 
extant evidence suggests that the impact of pharmacokinetic interaction is minimal. 
Combined treatment with CIT and HAL (Syvalahti et al., 1997) or CIT and OLZ (Botts et 
al., 2008) did not cause significant changes in the plasma concentrations of HAL or OLZ in 
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humans and possibly in rats. This leaves the pharmacodynamic interaction as the most likely 
factor contributing toward the enhanced antiavoidance effect. Indeed, several studies have 
reported that the central (brain) effects of HAL and OLZ are enhanced by CIT or other 
SSRIs. For example, Waldmeier and Delini-Stula (1979) reported that CIT potentiated the 
increase in striatal deaminated DA metabolites (homovanillic acid and 3,4-
dihydroxyphenylacetic acid) induced by HAL. Behaviorally, CIT also potentiated HAL-
induced catalepsy and its antagonism of apomorphine-induced stereotypies. Huang et al. 
(2006) found that CIT increased extracellular DA and norepinephrine efflux in rat medial 
prefrontal cortex induced by risperidone. Others have also shown that fluoxetine increases 
the release of DA and norepinephrine in the medial prefrontal cortex induced by OLZ (Koch 
et al., 2004). These augmented neurochemical effects by CIT on HAL or OLZ may explain 
the potentiated antiavoidance effect in the present study and the potentiated therapeutic 
effects on affective symptoms in the clinic (Zink et al., 2010). Because the antipsychotic 
action, as well as the antiavoidance effect of HAL and OLZ, is shown to be mediated by the 
antagonism of D2 receptors (Wadenberg et al., 2001; Li et al., 2010), CIT may increase the 
antagonistic action of HAL and OLZ on D2 receptors through its selective inhibition of 
reuptake of 5-HTand increase of 5-HTrelease in the medial prefrontal cortex (Huang et al., 
2006). Another possibility is that the increased level of 5-HT by CIT treatment may 
stimulate 5-HT2C receptors to exert a disruptive effect on avoidance responding. This 
hypothesis is supported by the evidence showing that 5-HT2C receptor agonists such as 2,5-
dimethoxy-4-iodo-amphetamine (DOI), 1-(3-chlorophenyl) piperazine (mCPP), and the 5-
HT2A/2C receptor agonist D-LSD disrupt the avoidance response (Wadenberg and Hicks, 
1999; Li et al., 2010). It is also consistent with the findings that the activation of 5-HT2C 
receptors decreases DA release in the nucleus accumbens and cell firing in the ventral 
tegmental area (Di Giovanni et al., 2000; Di Matteo et al., 2002), the mesolimbic DA 
system that is implicated in the CAR (Wadenberg and Hicks, 1999).
In recent years, we have shown that the repeated administration of HAL and OLZ induces a 
behavioral sensitization in the CAR model (Li et al., 2010; Mead and Li, 2010; Zhang and 
Li, 2012). This sensitization effect can be found in a challenge test (i.e. re-exposure to the 
drug) in which antipsychotic-treated animals show a stronger response (i.e. lower avoidance) 
to the drug than drug-naive animals (Mead and Li, 2009; Zhang et al., 2011; Zhang and Li, 
2012). It is also long-lasting, producing an effect that can be observed up to 3 weeks later 
(Mead and Li, 2009) and is subject to contextual and behavioral controls (Zhang and Li, 
2012). The results from the present study are consistent with these previous observations 
(Figs 4 and 7). In the current study, rats treated with HAL or OLZ (i.e. VEH + HAL or CIT 
+ HAL; VEH + OLZ or CIT + OLZ) in the CAR testing apparatus showed enhanced 
responses to a challenge dose of HAL or OLZ compared with those treated with the same 
drugs outside of the CAR apparatus. More interestingly, CIT treatment did not alter this 
long-term treatment effect of HAL or OLZ, as there was no significant difference between 
the two HAL (VEH + HAL or CIT + HAL) or two OLZ (VEH + OLZ or CIT + OLZ) 
groups on the challenge tests. Our recent work indicates that the activation of 5-HT2A/2C 
receptors by DOI (a 5-HT2A/2C receptor agonist) can attenuate HAL-induced and (to a lesser 
extent) OLZ-induced sensitization of avoidance responding (Li et al., 2010). The failure of 
CIT, but not DOI, to modulate HAL and OLZ sensitization might reflect differences 
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between changes in the synaptic levels of 5-HT produced by reuptake inhibition and the 
direct stimulation of 5-HT2A/2C receptors.
As mentioned in the Introduction section, most schizophrenic patients are treated with 
multiple psychotherapeutic drugs (ZumBrunnen and Jann, 1998; Zink et al., 2010). 
Combined SSRIs and antipsychotic therapies are also used widely in the treatment of major 
depressive disorders and especially in hard-to-treat and treatment-refractory patients 
(DeBattista and Hawkins, 2009). There are also drugs (e.g. Symbyax) with this drug 
combination built in (DeBattista and DeBattista, 2010). The current studies are important in 
understanding the psychological interactions associated with the polypharmacy treatment of 
schizophrenia-related spectrum disorders and comorbidities. The methodology of these 
studies effectively models the acute antipsychotic actions of drugs and their progressive 
effectiveness over time. The dynamics of drug efficacy may be of considerable importance 
in predicting both acute and long-term behavioral outcomes. As the current studies indicate, 
these drugs can have behavioral interactions that are well beyond the traditionally 
considered pharmacological interactions. These studies show that SSRIs, such as CIT, may 
augment the behavioral effects of both typical and atypical antipsychotics, although to date, 
this interaction has not been observed in a clinical setting. It is important to consider that at 
clinically relevant doses, drugs may interact at a behavioral level in ways that may either be 
efficacious or harmful in real-world use. Furthermore, these studies reinforce the idea that 
the experiential context of drug action may be an important part of drug efficacy and may 
play a role in drug maintenance and symptom relapse.
Besides its contribution in providing a preclinical approach to the study of polypharmacy in 
the treatment of schizophrenia, the present study is also important because it extends 
psychopharmacology research on antipsychotic drugs utilizing a Pavlovian DDC paradigm 
(Li et al., 2009). First, it shows that an instrumental conditioned active motor behavior can 
also be used as a valid index to evaluate the drug conditioning effect. This is different from 
many previous drug conditioning studies that typically use simple physiological measures or 
reactive responses, such as drug-induced thermic effects, heart rate, stomach emptying, 
muscle relaxation, or taste aversions (Wilkin et al., 1982; Revusky et al., 1989; Davey and 
Biederman, 1991; Reilly and Revusky, 1992; Biederman and Davey, 1993). Second, as 
discussed in our previous publication (Li et al., 2009), it introduces a new approach to 
examine the effects of DDC. In many drug conditioning studies, the drug conditioning effect 
is often indexed by some change in one or more of the intrinsic properties of the CS drug 
(Taukulis, 1996). For example, in a series of studies on the diazepam–haloperidol or 
diazepam–chlorpromazine conditioning (Taukulis and Brake, 1989; Taukulis et al., 1992), 
the drug conditioning was evidenced by the altered drug properties of diazepam, such as 
enhanced hypothermia, reduced muscle relaxation, and enhanced anxiolytic effect. In the 
present study, the conditioning effect was observed in the newly ‘acquired’ avoidance-
disruptive effect of CIT, which is not an intrinsic drug property of CIT. This approach 
provides an unequivocal demonstration of the DDC effect. Finally, it indicates that SSRIs 
can also be used as a CS drug to study the behavioral and neurobiological mechanisms 
underlying drug–drug interactions. Together with our previous work with chlordiazepoxide 
Sparkman and Li Page 11
Behav Pharmacol. Author manuscript; available in PMC 2016 February 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(Li et al., 2009), it appears that DDC may be a general process applicable to multiple 
psychotropic drugs.
Conclusion
Our results show that the concurrent use of CIT with HAL or OLZ caused a potentiation of 
the avoidance-disruptive effect of both antipsychotic drugs. Conversely, the behavioral 
effect of CIT was altered by HAL or OLZ through a DDC process, so that CIT acquired an 
additional avoidance-disruptive effect (an antipsychotic-like effect) after being combined 
repeatedly with HAL or OLZ. Our work provides a preclinical approach to examine the 
extent and mechanisms of drug–drug interactions among antipsychotics and antidepressants 
in the treatment of schizophrenia.
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Fig. 1. 
A schematic depiction of the experimental procedure in experiment 1. CAR, conditioned 
avoidance response; CIT, citalopram; HAL, haloperidol; VEH, vehicle.
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Fig. 2. 
Experiment 1: Number of avoidances (a) and escape failures (b) made by the rats in the four 
groups during the last predrug session, seven drug conditioning sessions, and two drug-free 
retraining sessions. Points represent mean±SEM. *Differs significantly (P < 0.05) from CIT 
+ VEH and VEH + VEH; #differs significantly (P < 0.05) from CIT + HAL. CIT, 
citalopram; HAL, haloperidol; VEH, vehicle.
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Fig. 3. 
Experiment 1: Number of avoidances during the CIT challenge test. All rats were injected 
with CIT (10 mg/kg, intraperitoneally) and tested 75 min later. Points represent mean±SEM. 
*Differs significantly (P < 0.05) from CIT + VEH and VEH + VEH. CIT, citalopram; HAL, 
haloperidol; VEH, vehicle.
Sparkman and Li Page 17
Behav Pharmacol. Author manuscript; available in PMC 2016 February 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 4. 
Experiment 1: Number of avoidances during the HAL challenge test. All rats were injected 
with HAL (0.025 mg/kg) and tested 60 min later. Points represent mean±SEM. *Differs 
significantly (P < 0.05) from CIT + VEH and VEH + VEH. Inset shows the number of 
avoidances from the drug-free retraining session conducted 1 day before. CIT, citalopram; 
HAL, haloperidol; VEH, vehicle.
Sparkman and Li Page 18
Behav Pharmacol. Author manuscript; available in PMC 2016 February 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 5. 
Experiment 2: Number of avoidances (a) and escape failures (b) made by the rats in the four 
groups during the last predrug session, seven drug conditioning sessions, and two drug-free 
retraining sessions. Points represent mean±SEM. *VEH + OLZ and CIT + OLZ differ 
significantly (P < 0.05) from the VEH + VEH or CIT + VEH; #CIT + OLZ differ 
significantly from the VEH + VEH and CIT + VEH. CIT, citalopram; HAL, haloperidol; 
OLZ, olanzapine; VEH, vehicle.
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Fig. 6. 
Experiment 2: During the CIT challenge test. All rats were injected with CIT (10 mg/kg, 
intraperitoneally) and tested 75 min later. Points represent mean±SEM. *Differs 
significantly (P < 0.05) from CIT + VEH and VEH + VEH. CIT, citalopram; OLZ, 
olanzapine; VEH, vehicle.
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Fig. 7. 
Experiment 2: Number of avoidances during the OLZ challenge test. All rats were injected 
with OLZ (0.5 mg/kg) and tested 60 min later. Points represent mean±SEM. *Differs 
significantly (P < 0.05) from CIT + VEH and VEH + VEH. #Differs significantly (P < 0.05) 
from VEH + OLZ, CIT + OLZ and VEH + VEH. Inset shows the number of avoidances 
from the drug-free retraining session conducted 1 day before. CIT, citalopram; OLZ, 
olanzapine; VEH, vehicle.
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